This paper is only available as a PDF. To read, Please Download here.
ABSTRACT
Objective
To determine if there is an association between the timing of testosterone discontinuation and ART outcomes.
Design
Retrospective cohort study.
Setting
Single academic center.
Patients
We included consecutive transgender patients seeking fertility preservation between October 2019 to April 2021. Patients who identified as transgender on androgens for >1 month on presentation were included.
Interventions
None.
Main outcome measures
A linear regression model was used to evaluate the effect of testosterone discontinuation duration on the number of mature oocytes retrieved.
Results
Eighteen patients (mean age 27.7 [SD 5.2] years, mean BMI 27.3 [SD 4.6] kg/m2, mean AMH 27.2 [SD 11.8], median AFC 20 [interquartile range (IQR) 14-32]) were included in the analysis. No patient underwent transition-related surgery (eg: oophorectomy, hysterectomy). None of the patients were previously pregnant. Mean time on testosterone was 44 (SD 29.6) months. Median time off testosterone until start of ovarian stimulation was 7.7 weeks (IQR 4.3-20.7) weeks. All patients underwent oocyte cryopreservation, except one who had embryo cryopreservation. Median total number of oocytes was 11 (IQR 7-14). Median number of mature oocytes was 7.5 (IQR 5-12) oocytes. The univariate regression model evaluating duration of time off testosterone prior to ART demonstrated no significant association with the outcome of mature oocytes (regression coefficient 0.19, 95% CI –0.13 to 0.50, p=0.226).
Conclusion
In a retrospective analysis of transgender patients recently on testosterone undergoing ART, there was no association detected between timing of testosterone cessation and number of mature oocytes.
Key words
Article info
Publication history
Accepted:
January 17,
2023
Received in revised form:
January 12,
2023
Received:
September 28,
2022
Publication stage
In Press Accepted ManuscriptFootnotes
Study type: Cohort study.
Funding: None.
Conflict of interest: Authors have nothing to disclose.
Attestation statement: Data regarding any of the subjects in the study has not been previously published unless specified.
Data sharing statement: Not applicable.
Trial registration: Not applicable.
Identification
Copyright
© 2023 The Author(s). Published by Elsevier Inc. on behalf of American Society for Reproductive Medicine.
User license
Creative Commons Attribution – NonCommercial – NoDerivs (CC BY-NC-ND 4.0) | How you can reuse 
Elsevier's open access license policy
Creative Commons Attribution – NonCommercial – NoDerivs (CC BY-NC-ND 4.0)
Permitted
For non-commercial purposes:
- Read, print & download
- Redistribute or republish the final article
- Text & data mine
- Translate the article (private use only, not for distribution)
- Reuse portions or extracts from the article in other works
Not Permitted
- Sell or re-use for commercial purposes
- Distribute translations or adaptations of the article
Elsevier's open access license policy
